Skip to main content

Table 1 Incident users of any blood glucose-lowering drug, oral antidiabetic drugs (OAD) and insulins only*

From: No increase in new users of blood glucose-lowering drugs in Norway 2006–2011: a nationwide prescription database study

   Any blood glucose-lowering drug (A10) OAD (A10B) Insulins only (A10A only)
Year Person years No of patients Incidence rate per 100,000 person years 95% confidence interval No of patients Incidence rate per 100,000 person years 95% confidence interval No of patients Incidence rate per 100,000 person years 95% confidence interval
Women           
2006 2,347,036 7,531 320 (314, 328) 6,752 288 (281, 295) 670 29 (26, 31)
2007 2,366,461 7,769 328 (321, 336) 6,927 293 (286, 300) 679 29 (27, 31)
2008 2,390,716 7,677 321 (314, 328) 6,717 281 (274, 288) 783 33 (31, 35)
2009 2,418,595 7,832 323 (317, 331) 6,912 286 (279, 293) 745 31 (29, 33)
2010 2,445,249 7,778 318 (311, 325) 6,817 279 (272, 286) 784 32 (30, 34)
2011 2,473,228 7,269 293 (287, 301) 6,369 258 (251, 264)   
Men           
2006 2,314,006 7,829 338 (331, 346) 6,830 295 (288, 302) 756 33 (30, 35)
2007 2,342,823 8,374 357 (350, 365) 7,326 313 (306, 320) 793 34 (32, 36)
2008 2,377,361 8,655 364 (356, 372) 7,498 315 (308, 323) 845 36 (33, 38)
2009 2,411,205 8,620 357 (350, 365) 7,453 309 (302, 316) 839 35 (33, 37)
2010 2,443,697 8,605 352 (345, 360) 7,475 306 (299, 313) 813 33 (31, 36)
2011 2,479,989 8,246 332 (325, 340) 7,131 288 (281, 294)   
Total           
2006 4,661,041 15,360 329 (324, 334) 13,582 291 (287, 297) 1,426 31 (29, 32)
2007 4,709,284 16,143 342 (338, 348) 14,253 303 (298, 308) 1,472 31 (30, 33)
2008 4,768,077 16,332 342 (337, 348) 14,215 298 (293, 303) 1,628 34 (33, 36)
2009 4,829,800 16,452 340 (335, 346) 14,365 297 (293, 302) 1,584 33 (31, 34)
2010 4,888,946 16,383 335 (330, 340) 14,292 292 (288, 297) 1,597 33 (31, 34)
2011 4,953,217 15,515 313 (308, 318) 13,500 273 (268, 277)   
  1. *Incident use is defined as no use of blood glucose-lowering drugs in the previous 24 months. In addition, for insulins only no OAD was dispensed in the subsequent 12 months.
  2. For insulins only users there are no data for 2011 due to the definition applied, requiring a 12 month follow up period after first insulin prescription filled.